Skip to main content
S&P 5007,712.57+0.28%DOW52,495.88+1.02%NASDAQ26,424.82-0.02%BTC$83,370.00+2.45%ETH$2,462.06+3.40%GOLD$4,153.00+0.25%OIL$98.64+0.84%
Smart Investors Daily
SID Premium
HI

NYSE · HIMS

Hims & Hers Health, Inc.

Healthcare · Medical - Equipment & Services

$29.21

Up+$1.06 (+3.77%)

Updated Oct 21, 2026, 11:49 AM

SID Score

3.5/10

Composite research score

Smart Money

62/100

Neutral

Market cap
8.28B
P/E ratio
63.9
Dividend yield
0.00%
52-week range
$13.74 – $57.45
Volume
10.55M
Avg. volume
27.1M

Price performance · HIMS

HIMS price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 20, 2026

HIMS closed at $29.21 after 21 trading sessions, down 4.01% for the selected period.

Last close
$29.21
Period change
-4.01%
Period low
$27.72
Period high
$30.92
Daily close
View OHLC price history
HIMS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 20, 2026$28.00$30.02$27.75$29.2110.55M
Oct 19, 2026$28.49$29.00$27.53$28.157.49M
Oct 16, 2026$29.51$30.00$27.53$28.0711.02M
Oct 15, 2026$26.875$29.65$26.33$29.3816.31M
Oct 14, 2026$29.26$29.6799$27.565$27.7211.07M
Oct 13, 2026$29.83$30.3822$28.7248$29.719.78M
Oct 12, 2026$30.92$31.79$30.33$30.648.94M
Oct 9, 2026$28.34$31.4473$28.3096$30.9216.03M
Oct 8, 2026$29.20$29.62$27.49$28.0615.06M
Oct 7, 2026$28.87$29.9184$28.75$29.545.47M
Oct 6, 2026$30.08$30.08$29.07$29.478.8M
Oct 5, 2026$28.91$30.04$28.80$29.678M
Oct 2, 2026$30.08$30.61$28.55$29.0010.08M
Oct 1, 2026$29.66$29.8841$28.64$29.307.94M
Sep 30, 2026$29.16$31.03$29.09$29.7914.52M
Sep 29, 2026$29.39$29.8337$28.295$28.706.58M
Sep 28, 2026$29.00$29.44$28.46$28.786.52M
Sep 25, 2026$29.48$29.76$28.565$29.428.2M
Sep 24, 2026$28.00$29.65$27.31$29.2816.71M
Sep 23, 2026$30.40$30.955$28.32$28.3911.89M
Sep 22, 2026$29.95$31.81$29.2167$30.4316.65M

Latest HIMS news

The latest Smart Investors Daily articles mentioning HIMS.

Stock researchCompany · Overview

HIMS research

Overview

Company profile and research snapshot.

Company profile

Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$42.83
Implied upside
—
Analysts
—
HIMS recent ratings
DateFirmRatingTarget
Aug 24, 2026Truist SecuritiesHold—
Aug 21, 2026BarclaysOverweight—
Aug 11, 2026Morgan StanleyEqual-Weight—
Aug 11, 2026TD CowenHold—
Aug 11, 2026B of A SecuritiesNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 17, 2026

Hims & Hers Health (HIMS) Dropped, So What Is Driving Attention Now?

Hims & Hers Health (HIMS) is back in focus after fresh product news, with Hers Hair now rolling out in the UK as a clinician-led subscription hair loss service for women. Recent price action tells a mixed story for Hims & Hers Health, with the share price down 4.46% over the last day and 9.22% over the past week, yet roughly flat over one month and weaker year to date. The 1-year total shareholder return has declined 43.61%, while the 3-year total shareholder return is very large at roughly...

Yahoo · Oct 17, 2026

Peptide Rule Change Could Matter For Hims Shares (HIMS)

Hims & Hers Health recently prepared for potential U.S. regulatory changes on peptide compounding by acquiring a California peptide facility and beginning ingredient testing, while also expanding Hers branded services into the U.K. hair loss market and launching Hers in Australia. The build out of peptide manufacturing, combined with clinician led programs like Hers Hair and new Australian reach, highlights management’s focus on owning more of the care and supply chain across higher...

Yahoo · Oct 17, 2026

Hims And Hers Health (HIMS) Stock May Trade At A Discount Despite Australia Launch

Hims & Hers Health has been a dramatic ride for shareholders over the past few years, yet recent share price weakness now has investors asking whether the current valuation is still supported by its sales base. With fresh product launches and international expansion grabbing headlines, the question is how much revenue power is already baked into today's price. Over the past 3 years the stock has delivered a return of about 368%, which puts a lot of pressure on the underlying sales profile to...

Yahoo · Oct 16, 2026

What Does Hims & Hers Health (HIMS) Expansion Into The UK And Australia Mean?

Hims & Hers Health (NYSE:HIMS) announced the launch of Hers personalised hair loss and wellness care in the UK in October 2026. The Hers UK rollout introduces tailored treatment plans for women's hair loss alongside broader wellness services through the company's telehealth platform. The business is also expanding its Hers care platform into Australia, adding another English speaking market to its international footprint. The Hers UK hair loss launch and Australia expansion open new chapters...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By